Prognostic impact of moderate secondary mitral regurgitation after optimized medical therapy in heart failure
Open Access
- 27 August 2026
- journal article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (5)
Abstract
Background and Aims: The prognostic significance of moderate secondary mitral regurgitation (MR) after optimized guideline-directed medical therapy (GDMT) in heart failure (HF) remains uncertain. Methods: We analysed 2468 ambulatory HF patients with paired transthoracic echocardiography at baseline and after 12 months of optimized GDMT. The primary composite was all-cause death or first heart failure hospitalization (HFH). Secondary endpoints included all-cause mortality and recurrent HFHs. Results: The mean age of patients was 66.2 ± 12.5 years, 70.6% were male, and the mean baseline left ventricular ejection fraction was 36.1% ± 13.6%. At 12 months, 80.5% of patients had no/mild MR, 15.6% had moderate MR, and 3.9% had severe MR. During a median 6.9-year follow-up, 1240 patients experienced the primary endpoint. Compared with no/mild MR, both moderate and severe MR at 12 months were independently associated with a higher risk of the primary composite endpoint [moderate: hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.47–1.95; severe: HR 1.81, 95% CI 1.44–2.29; both P < .001). Moderate MR was also independently associated with increased all-cause mortality (HR 1.54, 95% CI 1.32–1.79; P < .001) and recurrent HFHs (incidence rate ratio 2.17, 95% CI 1.81–2.60). Heart failure hospitalization rates were 9.03, 20.0, and 26.1 per 100 person-years in patients with no/mild, moderate, and severe MR, respectively. Among patients with moderate MR at 12 months, outcomes did not differ according to baseline MR severity. Conclusions: In this large-scale study, residual moderate secondary MR after 12 months of optimized GDMT was common and was independently associated with increased long-term mortality and HFHs.Keywords
This publication has 26 references indexed in Scilit:
- Registries on Transcatheter Edge-To-Edge Repair in Heart Failure: Current Evidence and Future PerspectivesEuropean Journal of Heart Failure, 2025
- Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical TherapyESC Heart Failure, 2024
- Evaluating Mitral TEER in the Management of Moderate Secondary Mitral Regurgitation Among Heart Failure PatientsJACC: Heart Failure, 2024
- Guideline-Directed Medical Therapy Assessment in Heart Failure Patients Undergoing Percutaneous Mitral Valve RepairESC Heart Failure, 2024
- Prognostic role of mitral regurgitation in patients with advanced heart failureEuropean Journal of Internal Medicine, 2023
- Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failureClinical Research in Cardiology, 2022
- Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHFEuropean Journal of Heart Failure, 2021
- Functional Mitral Regurgitation Predicts Short-Term Adverse Events in Patients With Acute Heart Failure and Reduced Left Ventricular Ejection FractionThe American Journal of Cardiology, 2017
- Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection FractionJACC: Heart Failure, 2017
- Secondary Mitral Regurgitation in Heart FailureJACC, 2015